Biotech

Human brain cells run new data centres in Singapore, Melbourne

AI is driving a surge in electricity demand, forcing governments and technology companies to search for more efficient computing systems

Ricky Lin, founder and CEO of Life3 Biotech, says the facility is intended to reflect Life3’s broader positioning beyond production, as well as its identity as a “social enterprise at heart”.

AI-powered microalgae hub to anchor Life3 Biotech’s position in sustainable proteins

Facility slated for completion in the fourth quarter of 2026 will house AI-driven bioreactors and a new visitor centre

Singapore’s high liveability index, talent-driven immigration policies and Asia-Pacific hub status will be key leverage factors to achieve strategic success, says the writer.

Singapore’s biotech strategy will benefit from collective, not competitive, thinking

Successful innovation requires a holistic risk-based approach beyond financial, infrastructure and manpower investments

Novartis will pay US$55 million upfront to combine its expertise in immuno-dermatology with the British firm’s drug discovery AI platform.

Novartis strikes deal with UK biotech for up to US$1.7 billion

Novartis is on a deal spree this year, including the US$12 billion acquisition of Avidity Biosciences

Singapore can excel through investment and reinvestment to ensure continued innovation.
BRUNCH

Forget chasing the next Pfizer: Singapore’s biotech future lies in innovation, not giants

The Republic may not have a major player to call its own, but licensing deals and early-stage breakthroughs can still count as wins

Six of this year's Emerging Enterprise finalists show how technology can transform the way we live, work and stay healthy.
EMERGING ENTERPRISE AWARDS 2025

Redefining industries through innovation and insight

These Emerging Enterprise Awards finalists are applying technology and data to make businesses more efficient and improve lives

Novartis, which focuses on heart, kidney and metabolic drugs, immunology, neuroscience and oncology, is looking to boost its portfolio.

Novartis agrees to buy Avidity in US$12 billion biotech deal

The full deal is expected to close in the first half of 2026, subject to the completion of the separation

Dr Roland Ong, founder and chairman of Nanyang Biologics,  says: “Biotech, AI and drug discovery are a long-term R&D process and continuous funding is required.”

Singapore biotech startup Nanyang Biologics bets on AI drug discovery platform to unlock revenue

After investing six years in R&D, the firm is heading to Nasdaq via a US$1.5 billion Spac deal as it lands its first client

Compared with other industries, biotech startups typically have long and uncertain timelines, as well as high capital requirements – all of which translate into perceived higher risk.

Challenging economic conditions raise the bar for nascent biotech startups as funding dries up

The pullback in science and tech funding in the US has cooled investor sentiment for now, but observers say more money may eventually flow into Asia and Europe